Page 39«..1020..38394041..5060..»

G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium

By Dr. Matthew Watson

RESEARCH TRIANGLE PARK, N.C., Oct. 16, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that multiple abstracts have been accepted for poster presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium, held October 27th and 28th in Boston, MA. A copy of the posters will be made available on the G1 Therapeutics website following the presentations here.

View post:
G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium

To Read More: G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
categoriaGlobal News Feed commentoComments Off on G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium | dataOctober 16th, 2023
Read All

Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR…

By Dr. Matthew Watson

Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for which has now been accepted by the Food and Drug Administration

Link:
Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR...

To Read More: Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR…
categoriaGlobal News Feed commentoComments Off on Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR… | dataOctober 16th, 2023
Read All

Nexcella Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

By Dr. Matthew Watson

More:
Nexcella Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

To Read More: Nexcella Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
categoriaGlobal News Feed commentoComments Off on Nexcella Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site | dataOctober 16th, 2023
Read All

Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

By Dr. Matthew Watson

LOS ANGELES, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”) today announced the successful completion of its 3rd engineering batch of BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 at its U.S. manufacturing site.

The rest is here:
Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

To Read More: Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
categoriaGlobal News Feed commentoComments Off on Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site | dataOctober 16th, 2023
Read All

Notable Labs Closes Merger Transaction With VBL Therapeutics

By Dr. Matthew Watson

- Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol “NTBL” effective at market open on October 17 -

Read more here:
Notable Labs Closes Merger Transaction With VBL Therapeutics

To Read More: Notable Labs Closes Merger Transaction With VBL Therapeutics
categoriaGlobal News Feed commentoComments Off on Notable Labs Closes Merger Transaction With VBL Therapeutics | dataOctober 16th, 2023
Read All

Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher’s bid and strategic vision for the Company

By Dr. Matthew Watson

Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company

Read the rest here:
Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company

To Read More: Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher’s bid and strategic vision for the Company
categoriaGlobal News Feed commentoComments Off on Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher’s bid and strategic vision for the Company | dataOctober 16th, 2023
Read All

BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute…

By Dr. Matthew Watson

Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS.

The rest is here:
BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute...

To Read More: BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute…
categoriaGlobal News Feed commentoComments Off on BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute… | dataOctober 16th, 2023
Read All

Jonathan Milner Issues Statement Responding to ISS Report

By Dr. Matthew Watson

Jonathan Milner Issues Statement Responding to ISS Report

Read more here:
Jonathan Milner Issues Statement Responding to ISS Report

To Read More: Jonathan Milner Issues Statement Responding to ISS Report
categoriaGlobal News Feed commentoComments Off on Jonathan Milner Issues Statement Responding to ISS Report | dataOctober 16th, 2023
Read All

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

By Dr. Matthew Watson

Call scheduled for Tuesday, October 17, 2023 at 8:00 a.m. ET Call scheduled for Tuesday, October 17, 2023 at 8:00 a.m. ET

See the original post:
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

To Read More: Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
categoriaGlobal News Feed commentoComments Off on Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures | dataOctober 16th, 2023
Read All

MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and…

By Dr. Matthew Watson

MBX 2109 was generally well-tolerated across all dosing cohorts

Read more here:
MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and...

To Read More: MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and…
categoriaGlobal News Feed commentoComments Off on MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and… | dataOctober 16th, 2023
Read All

Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023

By Dr. Matthew Watson

— 52-week results from the Phase 3 PaTHway Trial showed that the skeletal dynamics of adult patients with chronic hypoparathyroidism treated with TransCon PTH trended toward a new steady state closer to age-appropriate norms

View original post here:
Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023

To Read More: Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023
categoriaGlobal News Feed commentoComments Off on Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023 | dataOctober 16th, 2023
Read All

Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023

By Dr. Matthew Watson

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a live webcast at 8:00 a.m. ET / 2:00 p.m. CEST on Monday, October 23, 2023 to review interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN) presented at the European Society of Medical Oncology Congress (ESMO) 2023.

See the article here:
Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023

To Read More: Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023
categoriaGlobal News Feed commentoComments Off on Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023 | dataOctober 16th, 2023
Read All

Y-mAbs Announces Publication in Cancers

By Dr. Matthew Watson

Naxitamab-based chemo-immunotherapy significantly improves long-term outcomes when administered early during the course of treatment Naxitamab-based chemo-immunotherapy significantly improves long-term outcomes when administered early during the course of treatment

See more here:
Y-mAbs Announces Publication in Cancers

To Read More: Y-mAbs Announces Publication in Cancers
categoriaGlobal News Feed commentoComments Off on Y-mAbs Announces Publication in Cancers | dataOctober 16th, 2023
Read All

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

By Dr. Matthew Watson

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five presentations and one poster at the 14th Annual World ADC Conference, taking place in San Diego, October 16-19, 2023.

View post:
Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

To Read More: Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference
categoriaGlobal News Feed commentoComments Off on Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference | dataOctober 16th, 2023
Read All

Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer

By Dr. Matthew Watson

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Ms. S. Mishima Gerhart as Chief Regulatory Officer. Ms. Gerhart will lead the Company’s regulatory and quality strategies and activities.

The rest is here:
Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer

To Read More: Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
categoriaGlobal News Feed commentoComments Off on Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer | dataOctober 16th, 2023
Read All

Zymeworks Announces New Director Nominee

By Dr. Matthew Watson

VANCOUVER, British Columbia, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today announced that its board of directors will nominate Dr. Nancy Davidson for election to its board of directors at the Company’s upcoming annual general meeting of stockholders to be held on December 7, 2023.

Read more here:
Zymeworks Announces New Director Nominee

To Read More: Zymeworks Announces New Director Nominee
categoriaGlobal News Feed commentoComments Off on Zymeworks Announces New Director Nominee | dataOctober 16th, 2023
Read All

PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023

By Dr. Matthew Watson

SAN JOSE, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2023 after market close on Wednesday, November 1, 2023. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Visit link:
PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023

To Read More: PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023
categoriaGlobal News Feed commentoComments Off on PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023 | dataOctober 16th, 2023
Read All

Titan Pharmaceuticals Announces Appointment of Dato’ Seow Gim Shen and Brynner Chaim to the Company’s Board of Directors

By Dr. Matthew Watson

SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") is pleased to announce the appointments of Dato’ Seow Gim Shen and Brynner Chiam to the Company’s Board of Directors, effective October 12, 2023. Mr. Shen has also been appointed Chairman of the Board.

Originally posted here:
Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors

To Read More: Titan Pharmaceuticals Announces Appointment of Dato’ Seow Gim Shen and Brynner Chaim to the Company’s Board of Directors
categoriaGlobal News Feed commentoComments Off on Titan Pharmaceuticals Announces Appointment of Dato’ Seow Gim Shen and Brynner Chaim to the Company’s Board of Directors | dataOctober 16th, 2023
Read All

Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

By Dr. Matthew Watson

ROCKVILLE, Md., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Television personality and sports reporter Jay Glazer is opening up about his personal experiences with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses affecting approximately 10 million adults in the U.S. – and with Qelbree (viloxazine extended-release capsules), a nonstimulant medication for the treatment of ADHD.3

Follow this link:
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

To Read More: Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
categoriaGlobal News Feed commentoComments Off on Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey | dataOctober 16th, 2023
Read All

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

By Dr. Matthew Watson

FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that two abstracts detailing vebreltinib data were made available as part of the European Society of Medical Oncology Congress (ESMO) 2023 being held in Madrid, Spain from October 20-24, 2023.

Visit link:
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

To Read More: Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
categoriaGlobal News Feed commentoComments Off on Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023 | dataOctober 16th, 2023
Read All

Page 39«..1020..38394041..5060..»


Copyright :: 2024